Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
2. Actira
3. Avalox
4. Avelox
5. Bay 12 8039
6. Bay 12-8039
7. Bay 128039
8. Bay-12-8039
9. Bay-128039
10. Bay128039
11. Izilox
12. Moxifloxacin
13. Octegra
14. Proflox
1. 186826-86-8
2. Moxifloxacin Hcl
3. Avelox
4. Avalox
5. Vigamox
6. Moxifloxacin (hydrochloride)
7. Bay 12-8039
8. Bay-12-8039
9. Actira
10. Izilox
11. Moxifloxacine Hydrochloride
12. Chebi:7008
13. Moxifloxacin (as Hydrochloride)
14. Bay12-8039 Hcl
15. Moxeza
16. Al-15469a
17. Nsc-758875
18. (4as-cis)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6h-pyrrolol(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic Acid, Monohydrochloride
19. 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic Acid, Monohydrochloride
20. C53598599t
21. Bay-128039
22. Dsstox_cid_25921
23. Dsstox_rid_81224
24. Dsstox_gsid_45921
25. 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic Acid Hydrochloride
26. 7-[(4as,7as)-octahydro-1h-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
27. 186826-86-8 (hcl); 354812-41-2 (free Base)
28. Octegra
29. Vigamox (tn)
30. Avelox (tn)
31. Mflx
32. 1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
33. 1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-((4as,7as)-tetrahydro-1h-pyrrolo[3,4-b]pyridin-6(2h,7h,7ah)-yl)-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
34. 7-[(4as,7as)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic Acid;hydrochloride
35. Cas-186826-86-8
36. Moxifloxacin Hydrochloride [usan]
37. Moxivig
38. Vegamox
39. Actura
40. Moxifloxacin, Hcl
41. Unii-c53598599t
42. Ncgc00095130-01
43. 1-cyclopropyl-6-fluoro-8-methoxy-7-((4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
44. 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
45. Mfcd00949117
46. Bay12-8039
47. Moxifloxacin Hydrochloride [usan:usp]
48. Avelox In Sodium Chloride 0.8% In Plastic Container
49. Cpd000469185
50. 1-cyclopropyl-6-fluoro-8-methoxy-7-((4as,7as)-octahydropyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hydrochloride
51. Schembl37285
52. Mls001401368
53. Chembl1200735
54. Dtxsid4045921
55. Moxifloxacin Hcl [vandf]
56. Act02692
57. Amy25227
58. Bcp03623
59. Tox21_111439
60. Moxifloxacin Hydrochloride (jan/usp)
61. Akos015920132
62. Akos016015225
63. Tox21_111439_1
64. Ac-1275
65. Bcp9000963
66. Ccg-100924
67. Cs-1063
68. Ks-1181
69. Moxifloxacin Hydrochloride [mi]
70. Nc00174
71. Nsc 758875
72. Moxifloxacin Hydrochloride [jan]
73. Ncgc00271749-02
74. 3-quinolinecarboxylic Acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, Monohydrochloride
75. Hy-66011
76. Moxifloxacin Hydrochloride [mart.]
77. Smr000469185
78. Bcp0726000173
79. Moxifloxacin Hydrochloride [usp-rs]
80. Moxifloxacin Hydrochloride [who-dd]
81. Moxifloxacin Hydrochloride, >=98% (hplc)
82. M2479
83. S1465
84. Sw197554-3
85. D00874
86. Moxifloxacin Hydrochloride [orange Book]
87. Moxifloxacin Hydrochloride [ep Monograph]
88. 826m868
89. Moxifloxacin Hydrochloride [usp Monograph]
90. Q27107395
91. 186826-86-8 151096-09-2(base)
92. Moxifloxacin Hydrochloride, Vetranal(tm), Analytical Standard
93. Moxifloxacin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
94. Moxifloxacin For Peak Identification, European Pharmacopoeia (ep) Reference Standard
95. Moxifloxacin Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
96. Moxifloxacin Hydrochloride, United States Pharmacopeia (usp) Reference Standard
97. 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4as,7as)-octahydro-1h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride
98. 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4as,7as)-octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic Acid Hydrochloride (1:1)
99. 1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid Hcl
100. 1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylicacidhydrochloride
101. 7-[[(4as,8as)-2,3,4,4a,5,6,8,8a-octahydro-1h-1,7-naphthyridin-7-yl]methyl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic Acid;hydrochloride
Molecular Weight | 437.9 g/mol |
---|---|
Molecular Formula | C21H25ClFN3O4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 4 |
Exact Mass | 437.1517621 g/mol |
Monoisotopic Mass | 437.1517621 g/mol |
Topological Polar Surface Area | 82.1 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 727 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Avelox |
Drug Label | DESCRIPTIONAVELOX (moxifloxacin hydrochloride) is a synthetic broad spectrum antibacterial agent and is available as AVELOX Tablets for oral administration and as AVELOX I.V. for intravenous administration. Moxifloxacin, a fluoroquinolone, is availab... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 400mg base; 400mg |
Market Status | Prescription |
Company | Bayer Pharms; Bayer Hlthcare |
2 of 8 | |
---|---|
Drug Name | Moxeza |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | MOXEZA is a sterile solution for topical ophthalmic use.Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position. C21H24FN3O4HClMol Wt 437.9... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon Pharms |
3 of 8 | |
---|---|
Drug Name | Moxifloxacin hydrochloride |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | DESCRIPTIONAVELOX (moxifloxacin hydrochloride) is a synthetic broad spectrum antibacterial agent and is available as AVELOX Tablets for oral administration and as AVELOX I.V. for intravenous administration. Moxifloxacin, a fluoroquinolone, is availab... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet; Solution |
Route | Ophthalmic; Oral; ophthalmic |
Strength | 0.5%; eq 0.5% base; eq 400mg base |
Market Status | Tentative Approval; Prescription |
Company | Apotex; Aurobindo Pharma; Teva Pharms Usa; Torrent Pharms; Lupin; Teva Pharms; Dr Reddys Labs |
4 of 8 | |
---|---|
Drug Name | Vigamox |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | VIGAMOX (moxifloxacin HCl ophthalmic solution) 0.5% is a sterile ophthalmic solution. It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.Chemical Name:1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon Pharms |
5 of 8 | |
---|---|
Drug Name | Avelox |
Drug Label | DESCRIPTIONAVELOX (moxifloxacin hydrochloride) is a synthetic broad spectrum antibacterial agent and is available as AVELOX Tablets for oral administration and as AVELOX I.V. for intravenous administration. Moxifloxacin, a fluoroquinolone, is availab... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 400mg base; 400mg |
Market Status | Prescription |
Company | Bayer Pharms; Bayer Hlthcare |
6 of 8 | |
---|---|
Drug Name | Moxeza |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | MOXEZA is a sterile solution for topical ophthalmic use.Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position. C21H24FN3O4HClMol Wt 437.9... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon Pharms |
7 of 8 | |
---|---|
Drug Name | Moxifloxacin hydrochloride |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | DESCRIPTIONAVELOX (moxifloxacin hydrochloride) is a synthetic broad spectrum antibacterial agent and is available as AVELOX Tablets for oral administration and as AVELOX I.V. for intravenous administration. Moxifloxacin, a fluoroquinolone, is availab... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops; Tablet; Solution |
Route | Ophthalmic; Oral; ophthalmic |
Strength | 0.5%; eq 0.5% base; eq 400mg base |
Market Status | Tentative Approval; Prescription |
Company | Apotex; Aurobindo Pharma; Teva Pharms Usa; Torrent Pharms; Lupin; Teva Pharms; Dr Reddys Labs |
8 of 8 | |
---|---|
Drug Name | Vigamox |
PubMed Health | Moxifloxacin |
Drug Classes | Antibiotic |
Drug Label | VIGAMOX (moxifloxacin HCl ophthalmic solution) 0.5% is a sterile ophthalmic solution. It is an 8-methoxy fluoroquinolone anti-infective for topical ophthalmic use.Chemical Name:1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-... |
Active Ingredient | Moxifloxacin hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base |
Market Status | Prescription |
Company | Alcon Pharms |
Acute Exacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Complicated Intra-Abdominal Infection, Complicated Skin and Skin Structure Infections, Pelvic Inflammatory Disease, Treatment of acute bacterial sinusitis
Acute Exacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Complicated Intra-Abdominal Infection, Complicated Skin and Skin Structure Infections, Pelvic Inflammatory Disease, Treatment of acute bacterial sinusitis
Acute Exacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Complicated Intra-Abdominal Infection, Complicated Skin and Skin Structure Infections, Pelvic Inflammatory Disease, Treatment of acute bacterial sinusitis
Acute Exacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Complicated Intra-Abdominal Infection, Complicated Skin and Skin Structure Infections, Pelvic Inflammatory Disease, Treatment of acute bacterial sinusitis
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-30
Pay. Date : 2013-01-02
DMF Number : 16999
Submission : 2003-12-02
Status : Active
Type : II
Date of Issue : 2022-06-15
Valid Till : 2025-06-16
Written Confirmation Number : WC-0034
Address of the Firm :
NDC Package Code : 55111-064
Start Marketing Date : 2012-07-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Hanareum Farm Co., Ltd.
Registration Date : 2021-02-05
Registration Number : 20201211-209-J-529(2)
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : Chemical Technical Operations-Unit-II Plot No. 1, 75A, 75B, 105, 110, 111 & 112 Sri Venkateswara Co-operative Industrial Estate Bollaram Village, Jinnaram Mandal, Sangareddy District, Telangana, 502325 INDIA
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18789
Submission : 2005-09-19
Status : Active
Type : II
Date of Issue : 2022-07-28
Valid Till : 2025-06-16
Written Confirmation Number : WC-0036
Address of the Firm :
NDC Package Code : 58032-0131
Start Marketing Date : 2017-12-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-30
Pay. Date : 2013-01-02
DMF Number : 16999
Submission : 2003-12-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18789
Submission : 2005-09-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25368
Submission : 2011-08-31
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-10
Pay. Date : 2013-09-03
DMF Number : 24371
Submission : 2010-11-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20170
Submission : 2008-07-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23315
Submission : 2009-11-27
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-05-09
Pay. Date : 2013-04-24
DMF Number : 24003
Submission : 2010-07-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-07-11
Pay. Date : 2013-07-02
DMF Number : 20755
Submission : 2007-08-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23745
Submission : 2010-04-23
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-05-20
Pay. Date : 2014-03-14
DMF Number : 25362
Submission : 2011-10-25
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Emay Pharmaceuticals Pvt Ltd functions as the merchant export division of M/s. Bhavna Laboratories Pvt Ltd. As a GMP-approved API manufacturing company, we boast over three decades...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Zeon Pharma Industries India Pvt ltd is an ISO & GMP certified manufacturer of Bulk drugs & Intermediate and also supplies our associate manufacturing plant API / Semi finish form...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Orex Pharma has been manufacturing and exporting APIs, intermediates and specialty chemicals since 1979. It has a manufacturing site in Dombivli, 25 km from Mumbai. It has a skille...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
CAS Number : 151213-40-0
End Use API : Moxifloxacin Hydrochloride
About The Company : Hy-Gro Chemicals Pharmtek Pvt. Ltd. (Hy-Gro) is a fast growing pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Ad...
Pyridine-2,3-dicarboxylic acid
CAS Number : 89-00-9
End Use API : Moxifloxacin Hydrochloride
About The Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development ...
(S,S)-2,8-Diazabicyclo[4,3,0]-nonane
CAS Number : 151213-40-0
End Use API : Moxifloxacin Hydrochloride
About The Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development ...
1-Cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4...
CAS Number : 112811-71-9
End Use API : Moxifloxacin Hydrochloride
About The Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development ...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral, Topical
Dosage Form : Capsule
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : They are references multipurpose superdisintegrants, well-known and widely used in the pharmaceutical industry.
Pharmacopoeia Ref : EP/USP/JPE
Technical Specs : Not Available
Ingredient(s) : Sodium Starch Glycolate, Potato
Dosage Form : Softgel Capsule
Grade : Not Available
Application : Soft Gelatin
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : It is a natural pregelatinized maize starch that has been specially developed as a binder for wet granulation.
Dosage Form : Tablet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : Used as disintegrants, fillers and binders (once cooked) in nutraceutical and pharmaceutical dosage forms.
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Helps to manufacture Oral Dosage and Nutraceutical forms by acting as a filler-binder while serving as a fibre source for your customers.
Pharmacopoeia Ref : EP/USP/JP
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Syrup
Grade : Not Available
Application : Taste Masking
Excipient Details : Act as a bulk sweetener and vehicle in liquid dosage forms and as a humectant in semi solids.
Pharmacopoeia Ref : EP/USP, USP/FCC
Technical Specs : Not Available
Ingredient(s) : Sorbitol liquid crystallizing
Dosage Form : Tablet
Grade : Not Available
Dosage Form : Injectable / Parenteral
Grade : Not Available
Application : Parenteral
Excipient Details : A pyrogen-free sorbitol used as a carbohydrate source and osmotic diuretic agent in large volume parenteral injectables.
Dosage Form : Tablet
Grade : Not Available
Application : Disintegrants & Superdisintegrants
Excipient Details : It is a superdisintegrant that provides an efficient disintegration at low level of use
Dosage Form : Tablet
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Used as disintegrants, fillers and binders (once cooked) in nutraceutical and pharmaceutical dosage forms.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Corn Starch, Colloidal Silica
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?